Categories AlphaGraphs, Earnings, Technology

BIDU Earnings: Highlights of Baidu’s Q2 2023 financial results

Baidu, Inc. (NASDAQ: BIDU) on Tuesday reported higher revenues and adjusted earnings for the second quarter of 2023. Both operating segments — Baidu Core and iQIYI registering growth.

Baidu Q2 2023 earnings infographic

Total revenues of the China-based technology company increased 15% year-over-year to RMB34.06 billion ($4.70 billion) in the June quarter. The Baidu app had 677 million monthly active users at the end of the quarter, which is up 8% year-over-year.

Second-quarter adjusted earnings moved up to RMB22.55 per ADS ($3.11 per ADS) from RMB15.79 per ADS in the corresponding period of fiscal 2022. On an unadjusted basis, net income was RMB14.17 per ADS ($1.95 per ADS), compared to RMB9.97 per ADS last year.

Prior Performance

  • Baidu Q3 2022 earnings infographic
  • Baidu Q2 2022 earnings infographic

_________________________________________________________________________________________________________________

Stocks you may like:

Apple (AAPL) Stock

Microsoft (MSFT) Stock

Alphabet (GOOGL) Stock

International Business Machines Corp. (IBM) Stock

_________________________________________________________________________________________________________________

Most Popular

Nike (NKE) looks set to beat hurdles and build a brighter future

Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business

Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company

Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as

Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top